MedTrace Logo

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

NCT04883957 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-04-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule in the evaluated disease types.

Conditions

  • Mature B-cell Malignancies

Interventions

DRUG

BGB-11417

Film-coated tablets administered orally as specified in the treatment arm.

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Lu Zhang, M.D. · BeiGene (Suzhou) Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-05
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883957 on ClinicalTrials.gov